GlassScriptPhysician profile
Daryl Potter
NPI 1124442199
$5,924.96
in general payments reported to CMS, 2019-2025
37 companies · $592 in 2025
The $592 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,500 · 2022: $2,437 · 2023: $721 · 2024: $675 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.32 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,468.32 | 2022 | |
| Abbvie INC. | $1,128.42 | 2021-2025 | |
| Abbott Laboratories | $635.27 | 2021-2023 | Proclaim |
| Pfizer INC. | $273.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $242.39 | 2023-2024 | Farxiga, Tezspire |
| Novo Nordisk INC | $218.54 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Relievant Medsystems, INC. | $208.74 | 2022-2023 | Intracept |
| Boston Scientific Corporation | $197.47 | 2021 | |
| Nalu Medical, INC. | $140.32 | 2021 | |
| Lilly USA, LLC | $131.58 | 2021-2025 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $116.03 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $112.57 | 2021 | |
| Amgen INC. | $111.78 | 2021-2022 | |
| Medtronic, INC. | $99.85 | 2023-2024 | Intellis Adaptivestim, Synchromedii |
| Genzyme Corporation | $96.48 | 2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.